Introduction
Ablation has become the cornerstone of treatment for symptomatic atrial fibrillation (AF). 1 However, patient outcomes differ significantly depending on clinical characteristics and AF phenotype. 2 Recent evidence supports that left atrial (LA) remodelling is the most important factor in procedural success. 3 Methods to assess LA remodelling have evolved substantially, allowing deeper characterization of this progressive disease. The use of M-mode LA diameter (LAD) as the standard to evaluate LA remodelling has been progressively abandoned. 4 Instead, 3D imaging modalities have been shown to better define chamber volumes and shape, the presence and extent of myocardial fibrosis, and, with speckle tracking, the functional status of the LA. [5] [6] [7] [8] Most of these parameters, however, are confined to the research field. Left atrial sphericity, defined as the variation between actual LA shape and a perfect sphere, was first described in a single-centre MRI study as a new shape-based remodelling parameter strongly and independently associated to procedural failure: the higher the LA sphericity, the higher the probability of recurrence. 8 The aim of the study was to test the feasibility of assessment in a multicentre study (including different imaging modalities and ablation approaches) and to evaluate its capability to predict procedural outcomes.
Methods

Study design
This was a multicentre, observational study of a cohort of consecutive patients undergoing a first ablation procedure for paroxysmal and persistent AF. The main objective was to validate at multiple centres the predictive value of LA sphericity, assessed by 3D imaging, in the outcomes of AF ablation.
Study population
The study included consecutive patients from 1 January to 31 December 2013, who underwent a first ablation of symptomatic drug-refractory paroxysmal and persistent AF. Data were prospectively collected in institutional databases. Three-dimensional imaging of the LA was acquired prior to the procedure with computed tomography (CTA) or magnetic resonance angiograms (MRA). Patients with previous catheter or surgical LA ablation were excluded.
Minimum requirements for participating centres included a minimum of 25 AF ablations/year, pulmonary vein isolation (PVI) as procedural endpoint (radiofrequency or cryoenergy), pre-procedural 3D imaging in at least 50% of procedures, and data collection on baseline, procedural, and follow-up variables of interest in prospective institutional databases. All patients must have given consent for their inclusion in institutional databases. Nine of 16 centres screened met these criteria and participated in the study. Centres were categorized as high (> _100 AF ablations/year) or low (<100 AF ablations/year) volume according to previous literature. 9 A data set of 10 MRA of non-AF volunteers was analysed to explore LA spherical deformation in young, healthy individuals. Details of this population were previously reported. 10 The study protocol was approved by the hospitals' Ethics Committee.
3D image post-processing
Each centre applied its own institutional acquisition protocols for preprocedural CTA or MRA (detailed description in Supplementary data online, Table S1 ); post-processing, previously described in detail, 8 was centralized in a single centre. In summary, a 3D reconstruction of LA cavity (CT and MR) was created with the CARTO 3 V R (Biosense Webster, Diamond Bar, CA, USA) image integration plug-in after excluding PVs and LA appendage at their ostia. The resulting 3D model was imported to ADAS-AF TM (Galgo Medical, Barcelona, Spain) to calculate remodelling values including LA volume (LAV) and sphericity. Quantification of LA remodelling parameters was blinded to clinical and ablation data. Conceptually, LA sphericity quantifies the variation between the LA shape and a perfect sphere (Figure 1 ). Detailed mathematical formulae have been thoroughly specified in previous publications. 8 Briefly, LA sphericity is the coefficient of variation of the sphere (CVS), a non-dimensional parameter (independent of size) that captures the shape by dividing the standard deviation of the average radius (AR) of the sphere by the AR. The AR is calculated as the mean of distances between all points of the LA wall (3D model) and the centre of the LA. To facilitate understanding of the value, it is expressed as a percentage: (1 -CVS) Â 100. The aim of the study was to test the validity of LA sphericity categories in an external, heterogeneous, real-life cohort. For this purpose, the same cut-off values of the seminal paper were used to define spherical categories: Group 1 < _ 82.1% < Group 2 < 85.7% < _ Group 3.
Ablation procedure
Ablation was performed according to institutional protocols for paroxysmal and persistent AF, which included both contact and non-contact force sensing catheters, as well as first and second generation cryoballoon technologies. All centres using point-by-point radiofrequency ablation reported using wide antral circular ablation to achieve PVI.
All patients underwent pre-and post-procedural oral anticoagulation (international normalized ratio between 2 and 3) for at least 1 month before and after ablation. As a general rule, antiarrhythmic drugs (AAD) were discontinued > _5 half-lives before ablation (or > _1 week for amiodarone). In the majority of cases, transoesophageal echocardiography was performed before ablation to exclude the presence of LA thrombus. After transseptal puncture, a bolus of i.v. heparin was administered according to patient weight, followed by additional boluses/continuous infusion to maintain an activated clotting time of 250-350 s.
Radiofrequency ablation began with a 3D map using an electroanatomic mapping system (CARTO, Biosense Webster, Diamond Bar, CA, What's new?
• Atrial fibrillation (AF) ablation success is highly dependent on atrial disease stage. Methods to assess left atrial (LA) remodelling are crucial to determine disease progression and help to select optimal candidates.
• LA sphericity is a shape-based remodelling parameter independent of size. In a single-centre magnetic resonance imaging study was found to be associated to procedural success.
• The present study demonstrates, in a multicentre fashion, LA sphericity as the only imaging parameter with independent predictive value for recurrence after first AF ablation, after adjusting for covariates, regardless of AF phenotype, imaging modality, energy source, and centre experience.
• We propose a simple clinical-imaging 'LAGO' score that easily identified patients at high risk of procedural failure, and could be clinically useful to select optimal candidates for ablation. , Medtronic) was advanced, inflated, and positioned at each PV ostium until optimal occlusion was achieved. Cryoenergy was then delivered up to 240 s to achieve PVI, applying a bonus freeze as a general rule. Cryoenergy at right-side pulmonary veins was applied under phrenic nerve monitoring by pacing at superior vena cava.
Post-ablation management and follow-up
Treatment with AAD during the first 3 months after ablation was prescribed according to physician preference. As a general rule, Class IC drugs were first choice in patients with no structural heart disease and paroxysmal AF; Class III were preferred in cases of structural heart disease or persistent AF. Continuation of AAD therapy beyond 3 months post-ablation was based on documented AF recurrence or symptoms without any documented atrial arrhythmia.
Patient follow-up included a minimum of three visits at the outpatient clinic (3, 6 , and 12 months post-ablation) with 12-lead ECG and at least one 24-h Holter monitoring. When available, a more prolonged rhythm monitoring was performed with 2-, 3-, or 7-day Holter or implantable loop recorder (ILR, Reveal XT, Medtronic, MN, USA). Between scheduled visits, patients were instructed to seek medical care, to include an ECG whenever they presented with symptoms.
Primary endpoint was defined as any documented AF or flutter lasting more than 30 s by ECG, Holter, or ILR during follow-up. No blanking period was considered after the ablation procedure.
Statistical analysis
Continuous data are expressed as mean ± SD, median, and interquartile range (IQR) or number (percentage) as appropriate. The v 2 or Fisher exact test was used to compare proportions between groups. Student's t, Mann-Whitney U, one factor ANOVA, or Kruskal-Wallis tests were used to compare continuous variables between groups according to normality assumptions. Survival analysis using Cox proportional hazards model was used to identify univariate and multivariate predictors of AF recurrence after first AF ablation. A P-value of < _0.05 was considered significant. Analysis was performed using SPSS 19.0 statistical package (SPSS, Chicago, IL, USA).
Results
In total, 473 patients underwent AF ablation at the 9 participating centres in 2013. Three centres were categorized as high volume (33%). After exclusion of patients undergoing repeat AF ablation, those with no or suboptimal pre-procedural imaging, and those with inadequate follow-up, a cohort of 243 patients was included in the final data set (Supplementary data online, Figure S1 ). Most patients had paroxysmal AF (66%) and low CHA 2 DS 2 -VASc scores (< _1 in 67%). Ablation was performed a median of 43 (24-72) months after AF diagnosis, and radiofrequency was the most common energy source used for ablation (60%). There were 14 non-fatal complications (5.7%), due to vascular access complications (4), cardiac (3), and transient ischaemic attack, phrenic nerve palsy, acute pulmonary oedema, and haemoptysis (1 each). There were no deaths. Detailed baseline and procedural characteristics are listed in Table 1 .
After a median (IQR) follow-up of 457 (351-764) days, the overall recurrence rate after first procedure was 43.3%, occurring after a median (IQR) of 182 (92-367) days. Considering a 3-month blanking period, the recurrence rate dropped to 34.8%, with a median (IQR) time-to-recurrence of 305 (179-468) days (Supplementary data online, Figure S2 ). Three quarters of the patients received AAD during the first 3 months after ablation (Class I in 63% of cases), and 39% of all patients received ongoing treatment (Class I in 55% of cases). Repeat AF ablation was required in 17% of patients.
The majority (72.4%) of patients were monitored with 24-h Holter, 26.4% with more prolonged monitoring (48-h and 7-day Holter or ILR) and only 1.3% with ECG only. Recurrence was detected in 45.7%, 34.9%, and 66.7% of patients in each group, respectively (P = 0.24). Significant differences in the type of monitoring were found between sites (P < 0.01): five centres performed 24-h Holter only, two centres performed both 48-h and 7-day Holter in all patients, one centre performed 24-h Holter in 60% and ILR in 40%, and one centre 24-h Holter in 66.6% and ECG in 33.3% of patients. No association was found between AF recurrence and type of approach (P = 0.85) or type of monitoring (P = 0.125).
Left atrial remodelling
3D imaging was obtained with MRA in most cases (61%). Measurements of LA remodelling are detailed in Table 2 . Mean LA sphericity was 82.6 ± 3.5% and most patients (59%) showed spherical deformation (including Groups 2 and 3). Healthy controls showed significantly lower mean LA sphericity and LAV (76.50 ± 3.21 and 34.4 ± 8.6 mL, respectively; P < 0.001).
LA sphericity was weakly but significantly correlated with LAD (R = 0.342; P < 0.01) and LAV (R = 0.327; P < 0.001). Important collinearity was observed between LA sphericity and both LAD and LAV (eigenvalue of 0.001 and condition index 48).
Probability of recurrence after first procedure was greater in patients with spherical LA (Groups 2 and 3) compared to those with discoid LA (Group 1) after one (38% vs. 25%), two (58% vs. 44%) and three (73% vs. 47%) years of follow-up (log rank P = 0.026) (Figure 2) . Patients with spherical LA had higher BMI and more dilated LA, and more often received ablation in high-volume centres (Table 3) . Paradoxically, patients with a more spherical atrium had a lower proportion of high blood pressure and prior CV. It is noteworthy that AF phenotype and AF duration did not differ between LA sphericity groups, and no differences were observed in AAD use, cardioversion, or repeat ablation during follow-up. There was a higher proportion of nonparoxysmal AF in patients with dilated LA (43.3% vs. 22.0% assessed by LAD, P = 0.002 and 42.3% vs. 26.9% assessed by LAV, P = 0.012).
Predictors of ablation outcome
Univariate Cox regression analysis identified significant associations between adverse outcome after AF ablation and persistent AF, radiofrequency ablation, spherical LA, and dilated LA, whether assessed by LAD or volume. A trend toward increased risk of recurrence in patients with structural heart disease and those receiving additional subtrate ablation was also observed. Detailed description is provided in Supplementary data online, Table S2 .
Multivariate Cox proportional hazard analysis was performed to identify independent risk factors for recurrence ( Table 4) . Seven variables with significant association in the univariate Cox models and other previously reported independent predictors were included: high-volume centres, obesity, structural heart disease, CHA 2 DS 2 -VASc < _1, AF phenotype, time since AF diagnosis, and energy source. Due to serious collinearity problems, five separate models were tested: LA sphericity (Model 1), LAV (Model 2), LAD (Model 3), both LA sphericity and LAD (Model 4) and LA sphericity, LAV, and LAD (Model 5).
Paroxysmal AF and spherical remodelling were the only factors independently associated with recurrence across all models [hazard ratio (HR) % 0.5 and HR % 2, respectively]. CHA 2 DS 2 -VASc (< _1) showed independent predictive value with a HR % 0.5 when LAD was not included (models 1 and 2). Presence of structural heart disease remained significant only in model 1 (HR % 2).
LA dilation assessed by LAD was found to be independently associated with recurrence. When LA sphericity was included in the model, however, the significance did not persist. Remarkably, LAV was not associated with recurrence when adjusted for other covariates.
New scoring system to predict recurrences
A new clinical-and imaging-based model for pre-procedural risk stratification [Left Atrial Geometry and Outcome (LAGO) score] was built upon the identified predictors of recurrence: AF phenotype, presence of structural heart disease, CHA 2 DS 2 -VASc < _1, dilated LA, and spherical LA (scoring 1 point each). The area under the curve was 0.687 [95% confidence interval (95% CI) 0.610-0.765; P < 0.001]. Cut-off point of 3 (LRþ of 3; sensitivity 21%, specificity 94%) was independently associated with recurrence [HR 3.10 (95% CI 1.94-4.95); P < 0.001] (Figure 3 ). Patients scoring < _2 had better short-and mid-term outcome compared to those with > _3 points (probability of recurrence of 22% vs. 50% at 1 year and 35% vs. 82% at 3 years of follow-up).
Discussion
To our knowledge, this is the first study to validate the value of LA sphericity in predicting AF ablation outcome in a multicentre cohort. The study had three main findings: (i) LA sphericity was the only remodelling parameter with independent predictive value for AF ablation outcome regardless of AF phenotype, energy source, imaging modality, and operator experience; (ii) persistent AF was the only clinical factor associated with recurrences after adjustment for covariates; and (iii) a 5-item scoring system including clinical and imaging parameters better identified patients at very high risk of recurrence at mid-term follow-up.
LA remodelling in AF
Remodelling of the LA is the final pathway of a high number of cardiac diseases. Any condition generating volume or pressure overload of the LA could be considered a causal factor for AF development. In addition, AF itself promotes electrical, tissue, and structural changes of the LA, which promote the perpetuation of the arrhythmia ('AF begets AF'). 11 Structural remodelling has been classically defined as LA enlargement: both diameter and volume are increased in patients with AF, compared to those in sinus rhythm. 12 However, although LA size (especially volume) was a strong predictor of cardiovascular outcomes in patients in sinus rhythm, the predictive value in patients with AF was poor. 12 The present study is the first to also provide LA shape analysis of a young, healthy population, allowing an approximation to normality of spherical deformation. As with size, LA sphericity was increased in patients with diagnosed AF, compared to healthy controls in sinus rhythm. However, conclusions on the impact of AF in spherical deformation cannot be drawn from this analysis. Further comparison adjusted for covariates is warranted.
In our previous work, 8 LA sphericity was shown to be associated with risk factors such as hypertension, sleep apnoea, and presence of structural heart disease, as well as AF phenotype (higher sphericity in patients with non-paroxysmal AF). In another study, LA sphericity was strongly associated with thrombo-embolic events in patients with AF, compared to controls: the higher the spherical deformation the greater the likelihood of stroke. 13 In our cohort, all imaging parameters of LA remodelling were mildly but significantly correlated. It is noteworthy that AF phenotype was correlated with LA dilation but not with spherical deformation. This finding was confirmed in multivariate models, as both AF phenotype and LA sphericity were independently associated with recurrence. Similar findings with LA fibrosis were observed in the multicentre DECAAF study, 7 suggesting that degree of atrial remodelling is not necessarily related to a particular AF pattern. Although indication and predicted outcome for AF ablation is usually based on AF phenotype, the findings of our study and those of Marrouche et al. encourage a more refined assessment of LA disease before deciding the best therapeutic strategy for each patient.
AF ablation outcome
Current guidelines recommend LA size quantification to assess the remodelling process associated with AF. 1 In patients suitable for ablation due to symptomatic drug-refractory AF, an association between LA dilation and worse outcome has been suggested; however, due to the weakness of the evidence, current guidelines do not state any recommendation on patients' suitability for ablation in terms of LA size. 1 A recent meta-analysis evaluating individual baseline clinical and remodelling characteristics failed to find an association between LA size and recurrences. 2 Better characterization of the remodelling process associated with AF beyond size is therefore needed to improve ablation results. Evidence on more refined LA structural and functional parameters is growing and demonstrates strong association with the likelihood of procedural success. 6, 7, 14, 15 In this regard, previous single-centre series (106 patients) showed spherical deformation of the LA to be independently associated with the probability of recurrence after last AF ablation (mean of 1.4 procedures/patient). 8 The main limitations of our previous series were the bias of a single, high-volume centre with very experienced operators; single imaging modality (MRA); and not accounting for current state-of-the-art ablation tools (only radiofrequency without contactforce sensing was used). The present study was designed to overcome these limitations and test 3D-imaging remodelling predictors of AF ablation outcome after a first procedure in a multicentre cohort, including a wide spectrum of centre profiles (low vs. high volume, 16, 17 were consistent with published data. 16, 17 Demonstration of the independent predictive value of LA sphericity in this setting represents a clinically meaningful finding, providing strong evidence of its applicability in a wide range of clinical settings. Although LA size and recurrence were associated in univariate Cox analyses, both diameter and volume were rendered non-significant when adjusted for covariates. These findings mimic our previous report and those from Marrouche et al., suggesting that more advanced imaging characterization tools (LA sphericity or fibrosis) may be superior to size quantification alone for the precise definition of LA disease progression and may better stratify risk of recurrence. Contrary to previous reports, 18 the volume of AF ablation procedures per centre/year did not impact outcome.
Risk prediction scheme
LAGO score is a simple risk prediction model that combines five clinical and imaging variables, each of which provides additive predictive value for AF recurrence. This allows easy identification of patients with high scores (> _3 points) who are unlikely to remain in sinus rhythm at 3-year follow-up (<15% likelihood), and for whom ablation should not be advised as a rhythm control strategy.
Limitations
The main limitation of the study is its retrospective nature; nevertheless, the baseline, procedural, and follow-up data were extracted from prospective institutional databases. Image acquisition and ablation approach protocols were not homogeneous across centres. In our view, this constitutes a strength rather than a weakness of the study, as the results reflect the heterogeneous, real-life cases encountered in daily practice and confirms, to some extent, the broad applicability of LA sphericity. Exclusion of patients due to incomplete baseline or follow-up data could introduce a selection bias; however, these exclusions were mostly driven by incomplete pre-procedural evaluation and follow-up from the referral physicians and was not necessarily related to specific patient profiles. Rhythm monitoring was performed in most cases with repeated 24-h Holter, which might have underestimated the rate of recurrence; nevertheless, it was equally distributed in all groups, and impact on outcome data was limited. Rhythm monitoring was not homogeneous across centres; however, type of monitoring was not associated to detection of recurrence. Contrary to published evidence, our study failed to show an association between a more prolonged monitoring and increased detection of AF episodes. We analysed LA sphericity in a limited number of healthy young volunteers in an effort to characterize the normal LA shape, avoiding any potential confounding factor; there are inherent recruitment limitations in this population. We could not include a control group of non-AF individuals undergoing MRI for other purposes, as LA MR angiogram is not routinely performed in clinical practice outside the AF ablation setting and the likelihood of cardiovascular risk factors or comorbidities in this population would compromise the normality of sphericity data obtained. Data on MRI-detected fibrosis or speckle tracking were not obtained in the present study. Future research is warranted in order to provide insight on the relationship between LA shape, fibrosis, and function.
Conclusion
In this multicentre study, LA sphericity was the only imaging parameter with independent predictive value for recurrence after first AF ablation, after adjusting for covariates, regardless of AF phenotype, imaging modality, energy source, and centre experience. The simple clinical-imaging 'LAGO' score easily identified patients at high risk of procedural failure and could be clinically useful to select optimal candidates for ablation.
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